{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:06:39Z","timestamp":1784804799385,"version":"3.55.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004332","name":"Seoul National University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004332","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.dmpk.2020.12.001","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T21:23:40Z","timestamp":1606944220000},"page":"100374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Urinary metabolic markers reflect on hepatic, not intestinal, CYP3A activity in healthy subjects"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5799-4489","authenticated-orcid":false,"given":"Soyoung","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew HyoungJin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumin","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Chun","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seo Hyun","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SeungHwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung-Sang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In-Jin","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo-Youn","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.dmpk.2020.12.001_bib1","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","article-title":"Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation","volume":"138","author":"Zanger","year":"2013","journal-title":"Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.dmpk.2020.12.001_bib2","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2165\/00003088-199937060-00004","article-title":"Cytochrome P450 3A: ontogeny and drug disposition","volume":"37","author":"de Wildt","year":"1999","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.dmpk.2020.12.001_bib3","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1208\/s12248-019-0341-y","article-title":"Guidance for rifampin and midazolam dosing protocols to study intestinal and hepatic cytochrome P450 (CYP) 3A4 induction and de-induction","volume":"21","author":"Kapetas","year":"2019","journal-title":"AAPS J"},{"issue":"5","key":"10.1016\/j.dmpk.2020.12.001_bib4","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1038\/clpt.2013.128","article-title":"Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance","volume":"94","author":"Shin","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.dmpk.2020.12.001_bib5","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1208\/s12248-017-0090-8","article-title":"Distribution of exogenous and endogenous CYP3A markers and related factors in healthy males and females","volume":"19","author":"Lee","year":"2017","journal-title":"AAPS J"},{"issue":"4","key":"10.1016\/j.dmpk.2020.12.001_bib6","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.dmpk.2019.04.002","article-title":"Quantitative prediction of hepatic CYP3A activity using endogenous markers in healthy subjects after administration of CYP3A inhibitors or inducers","volume":"34","author":"Lee","year":"2019","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"3","key":"10.1016\/j.dmpk.2020.12.001_bib7","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.dmpk.2018.04.004","article-title":"Assessment of induced CYP3A activity in pregnant women using 4beta-hydroxycholesterol: cholesterol ratio as an appropriate metabolic marker","volume":"33","author":"Kim","year":"2018","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"53","key":"10.1016\/j.dmpk.2020.12.001_bib8","doi-asserted-by":"crossref","first-page":"e298","DOI":"10.3346\/jkms.2018.33.e298","article-title":"Assessment of hepatic cytochrome P450 3A activity using metabolic markers in patients with renal impairment","volume":"33","author":"Kim","year":"2018","journal-title":"J\u00a0Kor Med Sci"},{"issue":"2","key":"10.1016\/j.dmpk.2020.12.001_bib9","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/bcp.12833","article-title":"4beta-hydroxycholesterol correlates with dose but not steady-state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation?","volume":"81","author":"Gjestad","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.dmpk.2020.12.001_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0009-9236(95)90270-8","article-title":"Possible inhibition of hepatic metabolism of quinidine by erythromycin","volume":"57","author":"Spinler","year":"1995","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.dmpk.2020.12.001_bib11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1124\/dmd.109.028746","article-title":"Physiologically based pharmacokinetic model of mechanism-based inhibition of CYP3A by clarithromycin","volume":"38","author":"Quinney","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1016\/j.dmpk.2020.12.001_bib12","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.clpt.2004.10.002","article-title":"Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4\/5 activity and expression","volume":"77","author":"Pinto","year":"2005","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmpk.2020.12.001_bib13","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1517\/17425255.2011.553189","article-title":"The effect of grapefruit juice on drug disposition","volume":"7","author":"Hanley","year":"2011","journal-title":"Expet Opin Drug Metabol Toxicol"},{"issue":"7","key":"10.1016\/j.dmpk.2020.12.001_bib14","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0090-9556(24)15346-9","article-title":"Role of furanocoumarin derivatives on grapefruit juice-mediated inhibition of human CYP3A activity","volume":"28","author":"Guo","year":"2000","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"10.1016\/j.dmpk.2020.12.001_bib15","first-page":"1228","article-title":"Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins","volume":"25","author":"Schmiedlin-Ren","year":"1997","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmpk.2020.12.001_bib16","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0009-9236(03)00118-8","article-title":"Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice","volume":"74","author":"Greenblatt","year":"2003","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.dmpk.2020.12.001_bib17","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1177\/0091270003256059","article-title":"Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in\u00a0vivo by grapefruit juice","volume":"43","author":"Veronese","year":"2003","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.dmpk.2020.12.001_bib18","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0009-9236(99)70009-3","article-title":"Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in\u00a0vivo probe: effect of ketoconazole","volume":"66","author":"Tsunoda","year":"1999","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"10.1016\/j.dmpk.2020.12.001_bib19","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/0006-2952(94)90543-6","article-title":"Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily","volume":"47","author":"Gorski","year":"1994","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"10.1016\/j.dmpk.2020.12.001_bib20","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1097\/00008571-200206000-00009","article-title":"Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5\u22173 and \u22176, in a Japanese population","volume":"12","author":"Fukuen","year":"2002","journal-title":"Pharmacogenetics"},{"issue":"3","key":"10.1016\/j.dmpk.2020.12.001_bib21","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/bcp.12707","article-title":"4beta-hydroxycholesterol as an endogenous CYP3A marker in cancer patients treated with taxanes","volume":"80","author":"de Graan","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.dmpk.2020.12.001_bib22","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/FTD.0b013e318286ee02","article-title":"GC-MS-based quantitative signatures of cytochrome P450-mediated steroid oxidation induced by rifampicin","volume":"35","author":"Moon","year":"2013","journal-title":"Ther Drug Monit"},{"issue":"2","key":"10.1016\/j.dmpk.2020.12.001_bib23","doi-asserted-by":"crossref","first-page":"73","DOI":"10.12793\/tcp.2020.28.e10","article-title":"Development and validation of a method for the simultaneous quantification of endogenous steroids metabolized by CYP3A","volume":"28","author":"Lee","year":"2020","journal-title":"Transl Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.dmpk.2020.12.001_bib24","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.apsb.2016.07.012","article-title":"An update on the role of intestinal cytochrome P450 enzymes in drug disposition","volume":"6","author":"Xie","year":"2016","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"10.1016\/j.dmpk.2020.12.001_bib25","first-page":"14","article-title":"First-pass metabolism of midazolam by the human intestine","volume":"60","author":"Paine","year":"1996","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"10.1016\/j.dmpk.2020.12.001_bib26","doi-asserted-by":"crossref","first-page":"709","DOI":"10.5414\/CPP47709","article-title":"4beta-hydroxycholesterol as a marker of CYP3A4 inhibition in\u00a0vivo - effects of itraconazole in man","volume":"47","author":"Lutjohann","year":"2009","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.dmpk.2020.12.001_bib27","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/03602532.2016.1239630","article-title":"Perspective: 4beta-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A","volume":"49","author":"Mao","year":"2017","journal-title":"Drug Metab Rev"},{"issue":"1","key":"10.1016\/j.dmpk.2020.12.001_bib28","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/0009-9236(95)90068-3","article-title":"Interaction between grapefruit juice and midazolam in humans","volume":"58","author":"Kupferschmidt","year":"1995","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmpk.2020.12.001_bib29","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1177\/0091270006298359","article-title":"Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity: comparison with grapefruit juice","volume":"47","author":"Farkas","year":"2007","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"11","key":"10.1016\/j.dmpk.2020.12.001_bib30","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1021\/js980082d","article-title":"Role of P-glycoprotein and cytochrome P450 3A in limiting oral absorption of peptides and peptidomimetics","volume":"87","author":"Wacher","year":"1998","journal-title":"J\u00a0Pharm Sci"},{"issue":"10","key":"10.1016\/j.dmpk.2020.12.001_bib31","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1124\/dmd.114.059147","article-title":"Assessment of intestinal availability (FG) of substrate drugs of cytochrome p450s by analyzing changes in pharmacokinetic properties caused by drug-drug interactions","volume":"42","author":"Hisaka","year":"2014","journal-title":"Drug Metab Dispos"},{"issue":"2\u20133","key":"10.1016\/j.dmpk.2020.12.001_bib32","first-page":"99","article-title":"Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction","volume":"27","author":"Shen","year":"1997","journal-title":"Adv Drug Deliv Rev"},{"issue":"35","key":"10.1016\/j.dmpk.2020.12.001_bib33","doi-asserted-by":"crossref","first-page":"31534","DOI":"10.1074\/jbc.M201712200","article-title":"Metabolism of 4 beta -hydroxycholesterol in humans","volume":"277","author":"Bodin","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.dmpk.2020.12.001_bib34","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3109\/00365528809095917","article-title":"The role of enterocyte cholesterol metabolism in intestinal cell growth and differentiation","volume":"151","author":"Stange","year":"1988","journal-title":"Scand J Gastroenterol Suppl"},{"key":"10.1016\/j.dmpk.2020.12.001_bib35","doi-asserted-by":"crossref","first-page":"105439","DOI":"10.1016\/j.jsbmb.2019.105439","article-title":"Human steroid biosynthesis, metabolism and excretion are differentially reflected by serum and urine steroid metabolomes: a comprehensive review","volume":"194","author":"Schiffer","year":"2019","journal-title":"J\u00a0Steroid Biochem Mol Biol"},{"issue":"6","key":"10.1016\/j.dmpk.2020.12.001_bib36","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0090-9556(25)08440-5","article-title":"Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test","volume":"22","author":"Lown","year":"1994","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.dmpk.2020.12.001_bib37","doi-asserted-by":"crossref","first-page":"87","DOI":"10.2133\/dmpk.23.87","article-title":"Intestinal first-pass metabolism of CYP3A4 substrates","volume":"23","author":"Kato","year":"2008","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"1","key":"10.1016\/j.dmpk.2020.12.001_bib38","doi-asserted-by":"crossref","first-page":"28","DOI":"10.2133\/dmpk.25.28","article-title":"Contribution of intestinal cytochrome p450-mediated metabolism to drug-drug inhibition and induction interactions","volume":"25","author":"Galetin","year":"2010","journal-title":"Drug Metabol Pharmacokinet"},{"issue":"5","key":"10.1016\/j.dmpk.2020.12.001_bib39","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/jcph.1391","article-title":"4beta-Hydroxycholesterol as an endogenous biomarker for CYP3A activity: literature review and critical evaluation","volume":"59","author":"Penzak","year":"2019","journal-title":"J\u00a0Clin Pharmacol"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436720304353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436720304353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:55:32Z","timestamp":1761162932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436720304353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":39,"alternative-id":["S1347436720304353"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2020.12.001","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urinary metabolic markers reflect on hepatic, not intestinal, CYP3A activity in healthy subjects","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2020.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100374"}}